next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

Clicks: 208
ID: 139678
2008
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #34 of 73 articles by views in digest journal of nanomaterials and biostructures

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Michiko Yamamoto, Akira Takakura, Noriyuki MasudaDepartment of Respiratory Medicine, Kitasato University School of Medicine, Kitasato, JapanAbstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of combination regimens for lung cancer, particularly for small cell lung cancer, conducted in Japan and overseas have been promising. Amrubicin should be included among new treatment strategies especially for chemoresistant patients. Here, preclinical, pharmacological, and clinical data on the use of amrubicin for the treatment of small cell lung cancer are reviewed.Keywords: amrubicin, anthracycline, small-cell lung cancer, extensive disease
Reference Key
yamamoto2008drugnext-generation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Michiko Yamamoto;Akira Takakura;Noriyuki Masuda
Journal digest journal of nanomaterials and biostructures
Year 2008
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.